Attorney Docket No.: UCSD1140-1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Robert K. Naviaux

Art Unit:

1614

Application No.:

09/889,251

Examiner:

P. Spivack

Filed:

November 1, 2001

Title:

METHODS OF TREATMENT OF MITOCHONDRIAL DISORDERS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313

DECLARATION OF APPLICANT UNDER 37 C.F.R. § 1.131

Sir:

- I, Robert K. Naviaux, inventor of the above-identified application, do hereby declare and state that:
- 1. I am familiar with the above-identified patent application and the disclosure in the specification of methods for treating various disorders.
- 2. I have reviewed the Office Action mailed September 9, 2004, and I understand that claims 68 and 92 have been rejected, *inter alia*, under 35 U.S.C. § 102(a), as allegedly being anticipated by Loffler et al., Dihydroorotat-Ubiquinone Oxidoreductase Links Mitochondria In the Biosynthesis Of Pyrimidine Nucleotides, *Molecular and Cellular Biochemistry*, 174: 125–129 (1997). I further understand that Claims 67-80 and 88-94 have been rejected, *inter alia*, under 35 U.S.C. § 103(a), as allegedly being obvious over U.S. Patent No. 6,472,378 to von Borstel. I understand that the filing date of the von Borstel patent is August 31, 1998.
- 3. Prior to the publication date of Loffler et al. and the priority date of von Borstel, I had used the methods disclosed in the above-identified application. Particularly, I used uridine to achieve effective treatment of various mitochondrial disorders. Therefore, I conceived of and

PATENT

Attorney Docket No.: UCSD1140-1

Application No.: 09/889,251 Applicant: Robert K. Naviaux

Filed: November 1, 2001

Page 2

reduced to practice the methods claimed in the current application before the publication of the Loffler paper and before the priority date of the von Borstel patent. This can be evidenced by entries in my laboratory book. A copy of pertinent pages is attached herewith as Exhibit A. This can be also corroborated by the declaration of Dr. William Nyhan which is attached herewith as Exhibit B.

4. I further declare that all statements made herein of knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine, or imprisonment, or both under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

 $\frac{3}{3}05$

Robert K. Naviaux

STARTED URIDING I WEEK, IATO URIDINE 29TID Ellighte sestend-like und TO JUMP T ARMS RAISED OVERHEAD WHEN AIRD . NOW HORMAL WERE THESE TO BEFURE! 417 HAPPIN RINS ROWA BROAD-DASKO, ATAXIC HALL. => CHECK INTO EMPLOYER CLASS PRIVELESES START TRIACETYLURIDINE IF URIDINE WORKS 29 per Ny TiD x 3 mls, St" = 794 Bette oppetts Holding Suppy Cap 6929 TEGRATOR TROUGH MACONDE my : Sesono street

I fine motor to On one Bette attention again Bette previous to accomplate TASka Beta et waist eller des 4c 50m Hapatitis D () Nul Mitray Tellespore MIKE BELLETI

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Robert K. Naviaux

Art Unit:

1614

Application No.:

09/889,251

Examiner:

P. Spivack

Filed:

November 1, 2001

Confirmation No. 9760

Title:

METHODS OF TREATMENT OF MITOCHONDRIAL DISORDERS

DECLARATION BY DR. WILLIAM L. NYHAN

- I, William L. Nyhan, MD, Ph.D., am a professor of pediatrics with the School of Medicine, University of California at San Diego, where I am also a practicing physician (CV attached). I do hereby declare and state that:
- 1. I am familiar with the mitochondrial diseases and disorders that are proposed to be treated using the methods provided in the above-identified patent application. I have been treating patients having such disorders for many years.
- 2. I have reviewed claims that are pending in the above-identified application and understand that the claims are directed to methods for treating various mitochondrial diseases and disorders using uridine. I understand that the methods of treatment are generally encompassed in independent claims 67 and 91, and particular mitochondrial diseases and disorders to be treated are described in some of the dependent claims.
- 3. I first became aware of the fact that Dr. Naviaux suggested the idea of using uridine for treating various mitochondrial diseases and disorders in 1995. Both Dr. Naviaux and I attended "1995 Mitochondrial Diseases Symposium" held at Indianapolis, Indiana between June 30 and July 2, 1995. During one of our conversations in Indianapolis, Dr. Naviaux told me that he had learned that uridine is an important compound in the electron chain transport.

GT\6436749.1 101668-17

- 4. This discussion with Dr. Naviaux is very memorable to me for a number of reasons. First, the idea of using uridine had impressed me as a brilliant idea. Second, Dr. Naviaux is a colleague who also works at UCSD. For that reason, in 1995 I was in almost daily contact with Dr. Naviaux but had not heard about his idea of treatment using uridine previously.
- 5. I further declare that all statements made herein of knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine, or imprisonment, or both under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date

Dr. William L. Nyhg

GT\6416749.1 101668-17